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Abstract
Thymine DNA Glycosylase (TDG) plays a key role in active demethylation by
excising intermediates of 5-methylcytosine. The function of TDG is required for
embryonic development, as Tdg-null embryos die at E11.5. To bypass this embryonic
lethality, our lab generated conditional Tdg knockout (TDGCKO) mice. These mice
develop late-onset hepatocellular carcinoma (HCC), partly due to impaired Farnesoid X
Receptor (FXR) signaling. Interestingly, Fxr-knockout mice display a similar phenotype
and transcriptional profile to TDGCKO mice, prompting us to investigate a role for TDG in
FXR signaling. To this end, we generated Tdg/Fxr double-knockout (DKO) mice. We
also generated a novel Fxr-null mouse model using CRISPR/Cas9, which facilitated the
knockout of FXR through a 47-bp deletion event. We demonstrated that 3-week-old Fxrnull mice display impaired bile acid and glucose metabolism. Moreover, we
demonstrated a novel interaction between TDG and FXR in vivo. Collectively, these
findings implicate TDG as a coactivator of FXR signaling.
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Summary for Lay Audience
DNA can be modified by a process known as methylation. This modification can
be reversed by a counteracting process known as active demethylation. A key protein
involved in active demethylation is Thymine DNA Glycosylase (TDG). Mouse studies
have demonstrated that TDG is required for embryonic development. When TDG was
deleted from birth in mouse embryos, these embryos died twelve days post-conception.
Since the deletion of TDG from birth is lethal, our lab deleted TDG eight weeks
after birth to bypass this obstacle. This is known as a ‘conditional’ deletion; hence these
mice are called conditional TDG-knockout (TDGCKO) mice. Our lab found that TDGCKO
mice develop late-onset liver cancer, partly due to an increase in bile acids (BAs).
Excessive amounts of BAs can cause damage to the liver. Consequently, BAs are tightly
regulated. The main protein involved in regulating BAs is Farnesoid X Receptor (FXR).
Interestingly, FXR-knockout (FXRKO) mice develop late-onset liver cancer, which is
similar to TDGCKO mice. To this end, I aimed to generate TDG/FXR double-knockout
(DKO) mice by breeding FXRKO and TDGCKO mice together, predicting that DKO mice
will develop a more accelerated form of liver cancer. However, to generate DKO mice in
this manner, the genes for TDG and FXR would need to be on separate chromosomes.
Incidentally, TDG and FXR are on the same chromosome. Consequently, we used a
gene-editing technique that allowed us to bypass this hindrance. With this technique, we
generated a new FXRKO model which enabled us to subsequently generate DKO mice.
This technique functions by introducing various mutations into a gene of interest. I
showed that the specific mutation that occurred in our FXRKO mice was a deletion of 47
base pairs. I found that our FXRKO mice have significantly more BAs in the liver
compared to normal mice. Collectively, the preliminary data generated from our FXRKO
model is consistent with the published data from previous FXRKO models.
Finally, I investigated whether TDG plays a role in FXR function. I demonstrated
that TDG and FXR interact in mouse liver. Altogether, my results suggest that TDG plays
a coactivating role in FXR function.
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Introduction

1.1

Mammalian gene regulation
Cells have mechanisms to control the expression of genes. At the transcriptional

level, there are many regulatory elements in DNA that influence gene expression (e.g.
promoters, enhancers, and silencers). At the epigenetic level, gene regulation is achieved
through chromatin remodelling. Two well-established mechanisms involved in epigenetic
gene regulation are histone modifications and DNA methylation.
1.1.1 Gene expression and regulation
Gene expression is the process by which the DNA sequence of a gene is
converted into a functional gene product, which is normally a protein. This process is
further subdivided into two stages known as transcription and translation. During
transcription, the DNA sequence is used as a template to create a premature RNA
transcript through the function of RNA Polymerases (RNAPs) (Cramer, 2019). This
transcript is then processed into a mature RNA transcript (e.g. mRNA, tRNAs, rRNAs,
etc.) that functions according to its genetic sequence. If the transcript is an mRNA, it will
proceed to the next stage of gene expression which is translation. During translation, the
mRNA sequence is decoded by the ribosome to produce a protein. Considering that the
human genome contains approximately 20,000 protein-coding genes, this process
requires strict regulation in order to conserve energy, ensuring that genes are active in a
time and spatially dependent fashion (Guo, 2014).
At the transcriptional level, genes contain regulatory elements which help to
modulate their expression (Figure 1.1). A major regulatory element in a gene is the
promoter, which is the region that often signifies the start of the gene (Cramer, 2019).
The promoter region usually contains a core promoter, a short DNA sequence (~100 bp)
where the core transcriptional machinery (e.g. RNAP) binds to initiate transcription
(Andersson et al., 2015; Haberle and Stark, 2018; Andersson and Sandelin, 2020). The
core promoter possesses key elements for transcription initiation such as the transcription
start site (TSS), the TATA box, and the initiator element (INR) (Andersson et al., 2015;
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Haberle and Stark, 2018; Andersson and Sandelin, 2020). Other regulatory elements are
classified as ‘proximal’ or ‘distal’, relative to the core promoter. Distal elements—which
can be up to 1 million bp away from the core promoter— include enhancers (elements
that promote transcription), silencers (elements that repress transcription), insulators
(elements that prevent enhancer activation of neighbouring genes), and locus control
regions (LCR; elements that enhance expression of linked genes) (Maston et al., 2006;
Andersson and Sandelin, 2020). Proximal promoter elements —typically within 200 bp
upstream of the TSS— consist of response elements, which are consensus sequences that
act as binding sites for specific transcription factors (Haberle and Stark, 2018).
Regulatory elements function through the binding of transcription factors, which
can be broadly classified into two categories: general transcription factors (GTFs) and
specific transcription factors. GTFs (e.g. TFIIA, TFIIB, TFIID) bind to regulatory
elements within the core promoter and form a pre-initiation complex (PIC) with RNAPII
(Andersson et al., 2015; Haberle and Stark, 2018; Andersson and Sandelin, 2020). For
example, the TATA-binding protein (TBP), a subunit of TFIID, is a general transcription
factor that binds to the TATA box (Haberle and Stark, 2018). Specific transcription
factors bind to regulatory elements often found outside the core promoter (Andersson and
Sandelin, 2020). For example, the cAMP response element binding protein (CREB) is a
specific transcription factor that recognizes cAMP response elements (CREs). The
binding of specific transcription factors to regulatory elements causes recruitment of
coregulators. Generally, these coregulators do not bind to DNA specifically; rather, they
interact with transcription factors and can either function as coactivators or corepressors
(Maston et al., 2006). Transcription factors bound to enhancer elements recruit
coactivators; whereas transcription factors bound to repressor elements recruit
corepressors. For example, the coactivator CREB-binding protein (CBP/p300) interacts
with CREB and promotes the assembly of the PIC, thus enhancing the rate of
transcription at that locus. With over 3000 different transcription factors expressed in the
human genome, this heterogeneity contributes to the tissue-specific —and in some cases,
cell-type specific— gene expression patterns observed in humans, especially during early
development (Babu et al., 2004).

2

1.1.2 Epigenetic regulation of gene expression
Gene regulation also occurs at the epigenetic level. Epigenetics refers to heritable
changes in gene expression not caused by changes in DNA sequence (Fincham, 1997).
From a broad perspective, epigenetic regulation of gene expression occurs through
alterations in chromatin structure. Chromatin is organized as a multilayered structure with
varying degrees of compaction. At the most fundamental level, chromatin is composed of
repeating units known as nucleosomes (Kornberg, 1974). Nucleosomes are comprised of
147 bp of DNA wrapped around a histone octamer containing two copies each of histone
H2A, H2B, H3, and H4 (Kornberg, 1974; Quina et al., 2006). Each nucleosome is
connected by a segment of linker DNA bound to histone H1, which helps to condense the
chromatin into higher-order structures (Kornberg, 1974; Quina et al., 2006; Imhof, 2006).
The electrostatic interactions between the negatively charged DNA and the positively
charged histones facilitates the packaging of DNA into compact units.
There is approximately 3 billion bp of DNA that is highly condensed and
localized in the nucleus. However, for gene regulation to occur, the DNA must still be
accessible to the binding of various transcription factors and enzymes. This balance is
achieved in part through an epigenetic process known as chromatin remodelling. A key
mechanism involved in chromatin remodelling is histone modification, which can
promote gene activation or gene repression. Histones have an unstructured, flexible tail
domain that extends beyond the nucleosome core (Imhof, 2006). This tail consists of
residues that can undergo many forms of post-translational modifications including
acetylation, phosphorylation, methylation, and ubiquitination (Quina et al., 2006).
Generally, the histone modifications involved in gene activation recruit effector
complexes with histone acetyltransferase (HAT) activity and ATP-dependent chromatin
remodelling activity, which work in tandem to restructure the nucleosome and make the
DNA more accessible (Barrero et al., 2010). Moreover, acetylation of histones also
causes repulsion with DNA due to increased negative charge, leading to increased
accessibility of DNA (Barrero et al., 2010). Chromatin that is less condensed and thus
more accessible is known as euchromatin; in contrast, chromatin that is highly condensed
is known as heterochromatin. Correspondingly, euchromatin is found in genomic regions
3

that contain actively transcribed genes; whereas, heterochromatin is found in genomic
regions that are transcriptionally inactive (Quina et al., 2006; Gibb et al., 2011). Certain
histone marks are characteristic of euchromatin, such as trimethylation of H3 at lysine 4
(H3K4me3) and acetylation of H3 at lysine 14 (H3K14ac) (Zhang and Pradhan, 2014).
Histone marks for heterochromatin include trimethylation of H3 at lysine 9 (H3K9me3)
and lysine 27 (H3K27me3) (Zhang and Pradhan, 2014).
1.1.3 DNA methylation
DNA methylation is the second major mechanism involved in epigenetic
regulation. DNA methylation is the covalent addition of a methyl group to the C5
position of cytosine that generates 5-methylcytosine (5mC) (Illum et al., 2018). This
modification is catalyzed by DNA methyltransferase (DNMT) enzymes, which transfer
the methyl group from the universal methyl-donor S-adenosylmethionine (SAM) onto
cytosine (Bhattacharjee et al., 2016; Illum et al., 2018). DNA methylation occurs
primarily at cytosine-guanine (CpG) sites, which are unevenly distributed throughout the
genome (Illum et al., 2018). Genomic regions that contain a high density of CpGs (>550
bp region with an observed-to-expected CpG ratio of 0.65 or greater) are referred to as
CpG islands (CGIs) (Illum et al., 2018). CGIs are highly prevalent in the promoter
regions of most genes and they are also present in gene bodies (Vaissiere et al., 2008;
Illum et al., 2018). Although 80% of CpGs in the genome are methylated, promoter CGIs
are typically unmethylated under normal physiological conditions (Bhattacharjee et al.,
2016; Illum et al., 2018). Generally, DNA methylation represses gene expression,
especially in the context of promoter regions, as the steric hinderance caused by auxiliary
methyl groups restricts the binding of transcription factors to the promoter (Vaissiere et
al., 2008; Smallwood and Kelsey, 2012). Moreover, methylated CpG sites (mCpGs) are
recognized by mCpG binding proteins (MBPs) which in turn recruit effector complexes
with histone deacetylase (HDAC) activity, promoting heterochromatin formation
(Rottach et al., 2009; Illum et al., 2018).
DNA methylation impacts many biological processes that are essential to
mammalian development, including X-chromosome inactivation, genomic imprinting,
transposon silencing, and cell differentiation (Illum et al., 2018). Methylation patterns are
4

established early during embryonic development by the de novo methyltransferases
DNMT3a/DNMT3b (Vaissiere et al., 2008). These methylation patterns are maintained
through subsequent cell divisions by the function of DNMT1 with its associated cofactor
Ubiquitin-like containing PHD and RING finger domains 1 (UHRF1) (Rottach et al.,
2009). Alterations in 5mC patterns can lead to abnormal gene expression and genomic
instability. These aberrant methylation patterns are frequently observed in most cancers,
where promoter regions that are normally unmethylated (e.g. tumor suppressor gene
promoters) become hypermethylated, and regions that are normally hypermethylated (e.g.
transposable elements) become hypomethylated (Vaissiere et al., 2008; Zhang and
Pradhan, 2014). Deletion of any of the three major Dnmts (Dnmt1, Dnmt3a, Dnmt3b) in
mice resulted in severe genomic hypomethylation and lethality, either during or
immediately after embryonic development (Li et al., 1992; Lei et al., 1996; Jaenisch and
Bird, 2003).

5

Figure 1.1. Transcriptional regulatory elements. Transcription is initiated by binding
of the pre-initiation complex (consisting of RNAP and GTFs) at the core promoter. The
rate of transcription is influenced by the following regulatory elements, which are
typically distal relative to the promoter: enhancers, silencers, insulators, and LCRs.
Specific transcription factors bind to these elements and recruit coregulators that either
enhance or repress transcription. Figure is from Hawkins et al. (2018).
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1.2

DNA demethylation
Removal of 5mC occurs through passive or active mechanisms. Passive

demethylation involves the replication-dependent dilution of 5mC; whereas, active
demethylation is a replication-independent mechanism that requires modification of 5mC
followed by base excision repair. Active demethylation requires Thymine DNA
Glycosylase (TDG), which can excise 5fC and 5caC. The function of TDG is essential for
embryonic development.
1.2.1 Active demethylation
Once thought to be a static epigenetic mark, many studies have since established
that DNA methylation at many regions is highly dynamic (Wu and Zhang, 2011; Bhutani
et al., 2011; Kohli and Zhang, 2013; An et al., 2017). Removal of 5mC can occur through
two mechanisms: passive demethylation or active demethylation. Passive demethylation
involves an absence or a reduction of DNMT1 activity following successive rounds of
DNA replication (An et al., 2017). This occurs immediately after fertilization, when the
maternal genome is passively demethylated due to nuclear exclusion of DNMT1 or
UHRF1 (Wu and Zhang, 2014). In contrast, active demethylation, which occurs
independent of DNA replication, is the enzymatic process that results in the removal of
the methyl group from 5mC in part through base excision repair (BER) (Nabel et al.,
2012a). This also occurs immediately after fertilization— before DNA replication takes
place— when the paternal genome undergoes a rapid, global demethylation event that
generates several 5mC metabolites (Guo et al., 2011; Williams et al., 2012).
For many years, a demethylation pathway involving deamination of 5mC was
thought to be the predominant model for active demethylation in mammals. In this
model, 5mC is deaminated by the activation-induced deaminase/apolipoprotein B RNAediting catalytic component (AID/APOBEC) enzyme family, generating a thymine base
(Bochtler et al., 2017a). This thymine, now part of a G:T mispair, is then excised by
Thymine DNA Glycosylase (TDG) or its functional family member Methyl-CpG Binding
Domain 4 (MBD4), generating an apurinic/apyrimidinic (AP) site (Teperek-Tkacz et al.,
2011). This AP site is further processed by AP endonuclease 1 (APE1) before DNA
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Polymerase β incorporates an unmodified cytosine and the nick sealed by the XRCC1DNA Ligase IIIα complex (Figure 1.2) (Teperek-Tkacz et al., 2011). Spontaneous
deamination of 5mC does occur quite often in vivo, at a rate that is 2.2-fold higher than
deamination of cytosine to uracil (Shen et al., 1994). If left unrepaired, these deamination
events can result in G:T/G:U point mutations. Consequently, mCpG sites are hotspots for
point mutations in the genome. In fact, approximately one third of all oncogenic point
mutations can be attributed to spontaneous deamination at mCpG sites (Shen et al.,
1994). Nevertheless, the rate at which spontaneous deamination of cytosine/5mC occurs
cannot fully explain the vast number of oncogenic mutations that occur at CpGs
(Franchini et al., 2012). Alternatively, some researchers proposed that 5hydroxymethylcytosine (5hmC), a 5mC metabolite, could be deaminated by
AID/APOBEC to generate 5-hydroxymethyluracil (5hmU), which is excised by TDG
(Figure 1.2) (Wu and Zhang, 2011). However, several studies have since refuted this
deamination model pertaining to active demethylation, providing evidence for the current
model which involves succedent oxidation of 5mC (Figure 1.2) (Popp et al., 2010;
Bhutani et al., 2011; Teperek-Tkacz et al., 2011; Nabel et al., 2012b) . Firstly,
AID/APOBEC enzymes showed minimal deamination activity on 5mC or 5hmC in vitro;
in fact, these enzymes favour unmodified cytosines as their substrate over modified
cytosines (Nabel et al., 2012b). Secondly, if this deamination pathway was the main
pathway for active demethylation, then a severe (if not lethal) phenotype would be
expected in AID/APOBEC-null mice, which are in fact viable and fertile (Popp et al.,
2010). Taken together, this evidence suggests that deamination-induced demethylation is
unlikely to be the major mechanism for active demethylation.
The discovery of 5hmC in mammalian DNA largely contributed to the widely
accepted active demethylation model in mammals. In this model, 5mC is oxidized by a
member of the ten-eleven translocation (TET) enzyme family, generating 5hmC. 5hmC is
further oxidized by TETs into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC),
both of which are recognized and excised by TDG (Wu and Zhang, 2011). This excision
creates an AP site which is replaced with an unmethylated cytosine via BER (Figure 1.2)
(Wu and Zhang, 2011). The TET family —TET1, TET2, and TET3— are Fe2+ and 2oxoglutarate (2OG)-dependent dioxygenases that are capable of converting 5mC and
9

5hmC in vitro and in vivo (Williams et al., 2012). Each member possesses a conserved,
C-terminal catalytic core comprised of a double-stranded β-helix (DSBH) domain which
contains key residues that interact with Fe2+ and 2OG, and a cysteine-rich domain which
wraps around the DSBH to stabilize the overall structure and TET-DNA interaction (An
et al., 2017; Wu and Zhang, 2017). In addition to the catalytic domain, TET1 and TET3
have an N-terminal CXXC domain which is composed of two zinc finger motifs that can
bind DNA (An et al., 2017). This CXXC domain is not present in TET2, likely due to a
chromosomal rearrangement in the Tet2 gene during evolution which formed the
Idax/Cxxc4 gene that contains the CXXC domain (Zhu et al., 2020). Consequently, TET2
interacts with DNA indirectly through its partner IDAX to carry out its role in active
demethylation (Wu and Zhang, 2017). The CXXC domain binds preferentially to
unmethylated CpG-rich regions (An et al., 2017). TET1/3 are highly enriched at promoter
CGIs; whereas TET2 is mostly enriched at gene bodies and enhancer regions (An et al.,
2017). Interestingly, TET enzymes display tissue-specific differential expression patterns
(Williams et al., 2012). TET1 is predominantly expressed in embryonic stem cells
(ESCs), and its expression is gradually downregulated during differentiation; whereas
TET2 and TET3 levels increase or remain constant during differentiation (Rasmussen
and Helin, 2016; Melamed et al., 2018). TET2 is also expressed in ESCs, albeit at lower
levels, however it is robustly expressed in many adult tissues (Rasmussen and Helin,
2016; Melamed et al., 2018). TET2 works in conjunction with TET1 to ensure accurate
differentiation during ESC lineage specification, while playing a unique role in
hematopoietic stem cell differentiation (Melamed et al., 2018). TET3 is the
predominantly expressed TET in oocytes and zygotes, suggesting that TET3 is largely
responsible for the global demethylation of the paternal genome that occurs after
fertilization (Melamed et al., 2018).
The oxidized 5mC derivatives (5hmC, 5fC and 5caC) generated by TETs act as
intermediaries for active demethylation and can also accumulate at specific sites and
function as epigenetic marks for gene regulation (Figure 1.3). In mouse ESCs, 5hmC is
much more abundant than 5fC/5caC (>10-fold), as TETs convert 10% of 5mC to 5hmC,
and only a subset (1-10%) of 5hmC is converted to 5fC/5caC (An et al., 2017). This
implies that TET/TDG-mediated active demethylation usually stops at the 5hmC step
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because the presence of 5hmC is a more stable epigenetic mark compared to 5fC and
5caC, which are readily excised by TDG (An et al., 2017). Like TET1 expression levels,
5hmC levels are most abundant in ESCs, then gradually decrease during differentiation
(Guo et al., 2011). 5hmC levels in gene bodies positively correlate with gene expression
(Wu and Zhang, 2017). Counterintuitively, 5hmC levels are low at promoters with high
CpG density (e.g. promoters of highly expressed genes), even though TET1/3 are
enriched at these regions (Wu and Zhang, 2017). Rather, 5hmC is enriched at: (1)
promoters that have low CpG density and/or associated with bivalent domains, which are
regions that contain activating and repressive histone marks, typically found in
developmental genes that are repressed in ESCs but activated during differentiation, (2)
gene bodies of actively transcribed genes, and (3) distal regulatory elements including
enhancers, insulators, and regions flanking transcription factor binding sites (Wu and
Zhang, 2017). 5fC/5caC are mostly found in gene bodies of actively transcribed genes, at
bivalent promoters, and distal enhancers/insulators (Wu and Zhang, 2017). Through mass
spectrometry-based proteomics, specific reader proteins have been identified for 5hmC,
5fC, and 5caC, suggesting that each metabolite has a unique biological function (Spruijt
et al., 2013). Additionally, in vitro studies suggest that the presence of 5fC/5caC in DNA
causes stalling of RNAPII during transcription elongation, as RNAPII specifically
recognizes 5fC and 5caC and forms hydrogen bonds with the 5-carbonyl and 5-carboxyl
group, respectively (Kellinger et al., 2012; An et al., 2017). However, the exact function
of 5fC/5caC in gene regulation is not entirely clear.
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Figure 1.2. Active demethylation pathways. Several pathways have been proposed for
active demethylation such as the deamination pathway, the hydroxylation-deamination
pathway, and the current model which is the deamination-independent pathway. In the
current model, 5mC is successively oxidized by TETs to generate 5hmC, 5fC, and 5caC..
The 5fC and 5caC bases are excised by TDG leading to an abasic site that is repaired
through BER. The alternative pathways involve deamination of either 5mC or 5hmC to
thymine or 5hmU (respectively) prior to excision by TDG or other DNA glycosylases
such as MBD4 and SMUG1. Figure is from Dalton and Bellacosa (2012).
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Figure 1.3. Functions of oxidized 5mC derivatives. The process of active
demethylation generates several oxidized derivatives of 5mC including: 5hmC, 5fC, and
5caC. Each derivative is bound to specific reader proteins that may recruit chromatin
modifying enzymes. Although the exact function of 5fC/5caC in gene regulation is not
yet elucidated, 5fC/5caC may impact gene regulation by altering the conformation of
DNA and/or reducing the rate of elongation of RNAPII. Figure is from Wu and Zhang
(2015).
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1.2.2 Thymine DNA Glycosylase
TDG, a 410 amino acid enzyme, was initially identified as a BER enzyme
belonging to the mammalian uracil DNA glycosylase (UDG) superfamily which includes
Single-Strand-Selective Monofunctional Uracil-DNA Glycosylase 1 (SMUG1), MBD4,
and Uracil N-glycosylase 1/2 (UNG1/2) (Neddermann et al., 1996; Cortázar et al., 2007;
Sjolund et al., 2013). Within this superfamily, TDG belongs to the Mismatch Uracil DNA
Glycosylase (MUG) subfamily which all share a common α/β structural fold, a conserved
catalytic core, and variable N- and C-terminal tail regions (Figure 1.4) (Cortázar et al.,
2007; Sjolund et al., 2013). These tail regions undergo various post-translational
modifications that modulate the enzymatic activity of TDG (Xu et al., 2016; Koliadenko
and Wilanowski, 2020). The N-terminal tail domain (aa 1-122) contains a lysine-rich
region that undergoes acetylation by CBP, and adjacent serine residues that undergo
phosphorylation by protein kinase C alpha (PKCα) (Koliadenko and Wilanowski, 2020).
This domain allows TDG to bind to DNA, preferably at AP sites, which prevents
enzymatic degradation at these sites (Xu et al., 2016; Koliadenko and Wilanowski, 2020).
The C-terminal tail domain (aa 301-410) contains a K330 residue that undergoes
sumoylation by Small Ubiquitin-like Modifiers 1-3 (SUMO 1-3) (Sjolund et al., 2013).
TDG’s catalytic core (aa 123-300) contains the glycosylase domain responsible for
excising thymines and uracils from G:T/G:U mispairs (Sjolund et al., 2013). The
resulting AP site interacts with residues K246 and K248 within the catalytic core,
contributing to TDG’s high affinity for AP sites (Maiti et al., 2008; Popov et al., 2020;
Koliadenko and Wilanowski, 2020). Accordingly, dissociation of TDG from the AP site
is the rate-limiting step of the glycosylase reaction (Sjolund et al., 2013). SUMO
conjugation to the C-terminus of TDG promotes dissociation of TDG from the AP site
through steric hinderance and recruitment of APE1, which cleaves the AP site (Xu et al.,
2016).
Outside of G:T/G:U mismatch repair, TDG has many functional roles relating to
transcriptional regulation. As mentioned previously, TDG participates in transcriptional
regulation through its role in active demethylation. In fact, TDG is the only member of
the UDG superfamily that can excise 5fC and 5caC from double-stranded DNA (Dalton
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and Bellacosa, 2012). TDG also contributes to passive demethylation though its
interaction with DNMT3a, which inhibits the methylation activity of DNMT3a while
enhancing the glycosylase activity of TDG (Sjolund et al., 2013). Moreover, TDG is
known to interact with various members of the nuclear receptor (NR) superfamily,
including retinoic acid receptor (RAR), retinoid X receptor (RXR), estrogen receptor α
(ERα), etc. (Um et al., 1998; Chen et al., 2003). Generally, TDG’s interaction with these
NRs contributes to transcriptional coactivation. For example, TDG’s interacts with the
RAR/RXR heterodimer, enhancing its binding to retinoic acid response elements
(RAREs) in a ligand-independent manner (Um et al., 1998; Xu et al., 2016). When the
RAR/RXR heterodimer is activated by retinoic acid (RA), TDG recruits CBP and forms a
ternary complex that induces expression of RA target genes (Xu et al., 2016). Also, TDG
can interact in a ligand-dependent manner with ERα to stimulate its activity (Chen et al.,
2003; Xu et al., 2016). This interaction causes recruitment of a nuclear receptor
coactivator (NCOA) complex including steroid receptor coactivator 1 (SRC1) and SRC3,
which induces expression of ER target genes (Xu et al., 2016).
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Figure 1.4. TDG structural domains. TDG possesses a core catalytic domain (CAT)
flanked by two disordered tail regions. Contained within its N-terminal tail region is a
regulatory domain that undergoes various post-translation modifications such as
acetylation and phosphorylation. TDG possesses two SUMO-binding motifs (SBM1/2)
and undergoes sumoylation at K330. Figure is from Smet-Nocca et al. (2011).
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1.2.3 Phenotypic effects of TDG deletion
TDG is highly and ubiquitously expressed in developing mouse embryos,
particularly between days E7.5-E13.5 (Cortázar et al., 2007). Afterwards, its expression
is enriched in specific tissues including the intestine, lungs, kidney, thymus, and liver
(Cortázar et al., 2007). TDG is involved in mesenchymal-to-epithelial transition, which
occurs in processes such as somatic cell reprogramming and organogenesis (Bochtler et
al., 2017b). TDG is the only DNA glycosylase that is essential for embryonic
development, as knockout of Tdg in mice resulted in embryonic lethality by day E12.5
(Cortázar et al., 2011). Interestingly, the absence of TDG in these embryos did not affect
the mutation frequency associated with BER deficiency, suggesting that the embryonic
lethality caused by Tdg deletion is likely due to epigenetic abnormalities rather than an
accumulation of mutations. Epigenetic abnormalities displayed in Tdg-null ESCs include
aberrant DNA methylation and irregular histone modifications in the promoter regions of
developmental genes (Cortázar et al., 2011). TDG is required for recruiting coactivators
like CBP and lysine methyltransferase 2A (KMT2A) to these promoters (Cortázar et al.,
2011). Embryonic deletion of Tdg resulted in a general loss of activating histone marks
and an increase of repressive histone marks at many genes in mouse embryonic
fibroblasts (MEFs) (Cortázar et al., 2011). Furthermore, Tdg-null ESCs showed a 5-10
fold increase in genomic 5fC and 5caC levels (Shen et al., 2014). Interestingly, the
embryonic lethality seen in Tdg-null mice was largely attributed to liver hemorrhage,
highlighting that TDG plays a role in proper liver development in the embryo. Overall,
these knockout studies support the essential role for TDG in maintaining epigenetic
stability in vivo.
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1.3

Hepatic metabolism
The liver performs many metabolic functions in the body including bile acid

synthesis. The Farnesoid X Receptor (FXR) is the master regulator of bile acid
homeostasis. FXR acts as a tumor suppressor in vivo by protecting against the
development of hepatocellular carcinoma.
1.3.1 Liver metabolism
The distinguishing feature of the liver is its regenerative capacity. Upon liver
injury, hepatocytes —the main parenchymal cell type of the liver (~80% by mass) —
transition from their typically quiescent state and undergo substantial proliferation to
replace necrotic tissue (Stanger, 2015). Hepatic injury can occur through bile acid (BA)
accumulation in the liver as a result of impaired bile flow (i.e. cholestasis), or
dysregulation of BA synthesis. BAs are amphipathic sterols with detergent-like properties
that can generate cytotoxic effects when present in high concentrations in the liver (Li
and Chiang, 2014). Accordingly, the synthesis and transport of BAs is highly regulated.
Primary BAs are synthesized from cholesterol primarily through the classical pathway
(Li and Chiang, 2014). This pathway is initiated by cholesterol 7a-hydrocxylase
(CYP7A1) which performs the rate-limiting step of this pathway by oxidizing
cholesterol. Primary BAs are conjugated with glycine or taurine to form bile salts which
are more soluble (Li and Chiang, 2014). Bile salts are then secreted into bile through the
apical membrane of hepatocytes by the bile salt export pump (BSEP), where they are
stored in the gall bladder as mixed micelles to prevent damage to the bile duct (Li and
Chiang, 2014). Following postprandial stimulation, bile salts are secreted into the
intestine, where they become deconjugated and converted into secondary bile acids to
facilitate the absorption of lipids and vitamins (Li and Chiang, 2014). Most BAs (~95%)
are reabsorbed by ileal enterocytes via the apical sodium-dependent bile acid transporter
(ASBT), and then release into portal circulation via organic solute transporters α/β
(OSTα/β). Finally, BAs are taken up at the basolateral membrane of hepatocytes via the
sodium taurocholate cotransporting polypeptide (NTCP) to undergo enterohepatic
circulation (Figure 1.5) (Li and Chiang, 2014).
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Figure 1.5. Bile acid synthesis and transport. Primary bile acids (BAs) are synthesized
from cholesterol in the liver, primarily through a classical pathway and also through an
alternative pathway. BAs are then conjugated to glycine/taurine and secreted into bile via
BSEP. ~95% of BAs are reabsorbed in the intestine via ASBT where they are converted
to secondary BAs. BAs are then released into portal circulation via OSTα/β. BAs in the
portal blood are then reabsorbed into hepatocytes by NTCP or OATP to undergo
enterohepatic circulation. Figure is from Cheng et al. (2014).
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1.3.2 FXR
The farnesoid X receptor (FXR, also referred to as FXR or Nr1h4) —a bile acid
receptor that is highly expressed in the liver and intestine—is the master regulator of bile
acid homeostasis (Zhu et al., 2011). There are two known FXR genes, FXR (Nr1h4)
and FXR (Nr1h5) (Zhang and Edwards, 2008). While FXR represents a functional
receptor in mice, it constitutes a pseudogene in human and primates (Zhang and Edwards,
2008). FXR belongs to the nuclear receptor (NR) superfamily, which are ligand-activated
transcription factors that regulate the expression of target genes (Zhu et al., 2011).
Generally, NRs share a common structure: (1) a highly conserved N-terminal DNAbinding domain composed of two zinc-finger motifs that recognize specific response
elements, (2) a variable N-terminal transactivation (AF-1) domain responsible for
modulating transcriptional activity through interactions with cofactors in a ligandindependent manner, (3) a C-terminal ligand-binding domain involved in dimerization of
nuclear receptors, (4) a flexible hinge region that links that DNA-binding domain with
the ligand-binding domain, and (5) a C-terminal transactivation (AF-2) domain that
modulates transcriptional activity in a ligand-dependent manner (Zhu et al., 2011; Li and
Chiang, 2014) (Figure 1.6). In the absence of BAs, FXR is bound to FXR response
elements (FXREs) as a heterodimer with RXR in association with a host of corepressors
(Zhu et al., 2011). Binding of chenodeoxycholic acid (CDCA)—the most efficacious
ligand of FXR— to the ligand-binding domain triggers a conformational change in FXR
which releases the corepressors and recruits coactivators, promoting the expression of the
target gene (Zhu et al., 2011; Ding et al., 2015). The predominant FXR target gene
relating to bile acid homeostasis is small heterodimer partner (SHP), which belongs to the
‘orphan’ subfamily of NRs because it lacks a known endogenous ligand (Zhang and
Edwards, 2008). Furthermore, SHP cannot bind to DNA because it lacks a DNA-binding
domain, hence SHP regulates gene expression by acting as a corepressor (Zhang and
Edwards, 2008). FXR-mediated induction of SHP results in downregulation of CYP7A1,
as SHP inactivates the NRs that contribute to basal expression of CYP7A1, which are
liver receptor homologue-1 (LRH-1) and hepatocyte nuclear factor 4 (HNF4) (Ding et al.,
2015). Ultimately, the BA-induced activation of FXR results in a decrease in BA
synthesis in the liver through downregulation of CYP7A1, which is the rate-limiting
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enzyme in the classical BA synthesis pathway (Figure 1.7). This negative feedback
response is one of the mechanisms involved in maintaining BA homeostasis. FXR also
functions in the intestine to regulate BA synthesis (Figure 1.7). FXR activation in the
small intestine induces expression of fibroblast growth factor 15/19 (FGF15/FGF19),
which is secreted to the liver where it binds fibroblast growth factor receptor 4 (FGFR4)
found on hepatocytes, initiating a signaling transduction cascade that represses CYP7A1
expression (Zhu et al., 2011). In addition to regulating BA synthesis, FXR regulates BA
efflux by inducing expression of BSEP and OSTα/β, which promote enterohepatic
circulation of BAs (Zhu et al., 2011). Outside of BA homeostasis, FXR also regulates
hepatic glucose homeostasis. FXR regulates the expression of several genes involved in
the gluconeogenic pathway, including phosphoenol-pyruvate carboxykinase (PEPCK),
fructose1,6-bis phosphatase (FBP1) and glucose-6-phosphatase (G6Pase) (Jiao et al.,
2015). The role of FXR activation on hepatic gluconeogenesis is not yet clear (Jiao et al.,
2015). Some studies demonstrate that FXR activation inhibits gluconeogenesis through
downregulation of PEPCK and G6Pase in human hepatoma cells; however, other studies
demonstrate that FXR activation promotes gluconeogenesis through PEPCK upregulation
in primary hepatocytes (De Fabiani et al., 2003; Cariou et al., 2005; Stayrook et al., 2005;
(Zieve et al., 2007).
The murine Fxrα gene (Nr1h4) contains 11 exons and two different promoters
that initiate transcription from either exon 1 or exon 3 (Huber et al., 2002; Jiao et al.,
2015). Four isoforms (FXRα1, FXRα2, FXRα3, FXRα4) are generated through
differential promoter usage and alternative splicing between exons 5 and 6, which
produces a four amino acid (MYTG) insert immediately adjacent to the DNA-binding
domain (Huber et al., 2002; Jiao et al., 2015). The full-length FXR protein (FXRα3)
contains only 9 of the 11 potential exons (Figure 1.6) (Huber et al., 2002; Jiao et al.,
2015).
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Figure 1.6 FXR structural domains and isoforms. The FXR gene is composed
of 11 exons and 10 introns. FXR encodes four isoforms (FXRα1-4) through the use of
two different promoters and alternative splicing between exons 5 and 6 which produces
an MYTG insert in FXRα1 and FXRα3. FXR’s structural domains include the AF1/AF2
activation domains, the DNA-binding domain (DBD), the hinge domain, and the ligandbinding domain (LBD). Figure is from Modica et al. (2010).
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Figure 1.7. FXR signaling pathways. FXR is bound to FXREs as a heterodimer with
RXR in association with corepressors. FXR is activated by the binding of BAs.
Activation of FXR in the liver induces the expression of SHP which represses CYP7A1
expression, preventing BA synthesis in the liver. Activation of FXR in the intestine
induces the expression of FGF15, which is secreted into the liver where it binds to its
receptor FGFR4 to repress CYP7A1 expression. Figure is from Inagaki et al. (2005).
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To our knowledge, three Fxr knockout (FXRKO) models have been previously
described in the literature (Sinal et al., 2000) (Kok et al., 2003) (Bjursell et al., 2013).
Previous FXRKO models have been generated through deletion of either the ligandbinding domain or the DNA-binding domain. One model was generated through Cremediated deletion of exon 9 of the full-length FXR protein, which encodes a large portion
of the ligand-binding domain, in addition to deletion of the 3’UTR (Sinal et al., 2000). In
contrast, another model was generated through targeted deletion of exon 2 of the full
length FXR-protein, which encodes a segment of DNA-binding domain (Kok et al.,
2003). Lastly, a third model was generated through Cre-mediated deletion of exon 9 of
the full-length FXR protein without disrupting the 3’UTR (Bjursell et al., 2013).
Several FXRKO studies have been performed in mice establishing FXR’s role as a
tumour suppressor in vivo (Kim et al., 2007; Yang et al., 2007). FXR protects the liver
from cancer development caused by BA overload. FXRKO mice spontaneously develop a
late onset hepatocellular carcinoma (HCC) between 12 and 15 months of age and have
significantly higher levels of hepatic BAs (Kim et al., 2007; Yang et al., 2007).
Moreover, FXRKO mice show elevated fasting glucose levels, insulin resistance, and
glucose intolerance (Zhang et al., 2006). In humans, HCC incidence is correlated with
downregulation of FXR (Matsubara et al., 2013). HCC incidence in FXRKO mice can be
accelerated by deletion of interferon-γ (IFNγ), a pro-inflammatory cytokine that
modulates Fxr expression, and Shp (Anakk et al., 2011; Meng et al., 2012; Kim et al.,
2017). Since FXR and SHP function linearly in the BA synthesis pathway, it is expected
that Fxr should be epistatic to Shp, such that the phenotype observed in Fxr-null mice
should be similar to that of Fxr/Shp double-knockout (DKO) mice. However, the
phenotype displayed in Fxr/Shp DKO mice was much more severe than that of Fxr-null
or Shp-null mice (Anakk et al., 2011). The combined deletion of Fxr and Shp in mice
caused juvenile-onset cholestasis, resulting in a significantly higher accumulation of BAs
in the liver and serum compared to either knockout alone (Anakk et al., 2011; Kim et al.,
2017). This exacerbated phenotype in Fxr/Shp DKO mice demonstrates that Fxr and Shp
have nonoverlapping functions pertaining to BA homeostasis, despite their involvement
in a common molecular pathway.
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Interestingly FXRKO mice share a similar phenotype with conditional Tdg
knockout (TDGCKO) mice generated by Hassan et al. (2020) to bypass the embryonic
lethality of a constitutive Tdg knockout. In this mouse model, Tdg is deleted eight weeks
post-partum by a tamoxifen-inducible Cre-ERT2 under the control of the ubiquitin C
(UBC) promoter. Similar to FXRKO mice, TDGCKO mice develop a late onset HCC and
display symptoms associated with obesity and type 2 diabetes (T2D), such as increased
body weight, glucose intolerance, and the accumulation of primary bile acids with age
(Hassan et al., 2020). Through transcriptomic analysis, the metabolic abnormalities
observed in TDGCKO mice were attributed to a disruption in FXR signaling, as
metabolism and the primary BA synthetic pathway were highly dysregulated following
Tdg deletion (Hassan et al., 2020).
1.3.3 Hepatocellular carcinoma
Primary liver cancer is the second leading cause of cancer-related deaths
worldwide (Sia et al., 2017). HCC, the most common primary liver cancer, accounts for
90% of all primary liver cancers (Sia et al., 2017). HCC typically develops from a
background of cirrhosis due to chronic liver injury (Sanyal et al., 2010). Chronic liver
injury causes impairment of hepatocyte proliferation and subsequent activation of hepatic
stellate cells (HSCs), which are nonparenchymal, progenitor cells located in the space of
Disse (Gordillo et al., 2015). HSCs not only proliferate upon activation, but they also
differentiate into myofibroblasts and secrete collagen fibers and growth factors which
contribute to inflammation and scarring of the liver (i.e. fibrosis/cirrhosis) (Gordillo et
al., 2015). This scarring is exacerbated by the activation of Kupffer cells—specialized
immune cells resident within the sinusoid —which secrete cytokines that induce a proinflammatory immune response at the site of injury (Manco et al., 2018). Prolonged liver
regeneration during hepatocarcinogenesis leads to activation of oncogenic signaling
pathways such as insulin-like growth factor (IGF) signaling and Hippo signaling (Moeini
et al., 2012).
Established risk factors of HCC include alcoholism, hepatitis B, or hepatitis C
infection (Sanyal et al., 2010). More recently, T2D has been described as another risk
factor for HCC (Sanyal et al., 2010). T2D is characterized by insulin resistance,
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hyperglycemia, hyperinsulinemia, and inflammation, all of which have been implicated
in the progression of many cancers (Baffy et al., 2012; Yu et al., 2013; Allaire and Nault,
2016). T2D is associated with a 2 to 3-fold increase in the risk for HCC occurrence, with
this incidence being significantly higher in male diabetics compared to female diabetics
(Gao et al., 2013; Allaire and Nault, 2016). However, the molecular details implicating
HCC and T2D are not yet clear.

32

1.4

Rationale and hypothesis

Our lab has demonstrated that TDGCKO mice spontaneously develop a late-onset HCC
associated with T2D symptoms, including increased body weight, glucose intolerance,
and BA overload (Hassan et al., 2020). This hepatocarcinogenic phenotype was largely
attributed to impaired FXR signalling, suggesting that the loss of TDG negatively
impacts FXR signaling (Hassan et al., 2020). This notion is supported by the phenotypic
similarities between FXRKO and TDGCKO mice (Zhang et al., 2006; Kim et al., 2007;
Yang et al., 2007). Previous studies have demonstrated that TDG acts a coactivator of
various nuclear receptor signaling pathways, such as RAR and ERα signaling (Um et al.,
1998; Chen et al., 2003). However, a putative role for TDG in FXR signaling has not
been previously investigated. These observations prompted the following hypothesis and
aims for this study:
Hypothesis: TDG is an essential co-activator for FXR signalling in the liver and the loss
of Tdg in Fxr-null mice will cause epigenetic defects that accelerate the development of
HCC.
Aim 1. Characterize the molecular role of TDG in FXR signalling
Aim 2. Generate Tdg/Fxr DKO mice (Fxr-/- Tdgfl/fl CreERT2+/-) and characterize the
preliminary phenotype
For my first aim, I will attempt to characterize a novel role for TDG in FXR
signaling by testing a potential interaction between TDG and FXR in the liver. For my
second aim, I will utilize CRISPR/Cas9 genome editing to generate Tdg/Fxr DKO mice,
with the intent to generate a more accelerated HCC mouse model. Ideally, generation of
the Tdg/Fxr DKO mouse model would entail breeding of commercially available FXRKO
mice with our TDGCKO mice. However, Tdg and Fxr genes are linked on mouse
chromosome 10, separated by approximately 10 million bp (Figure 1.8A). Based on the
proximity of these genes, the probability of a recombination event at that locus is unlikely
(~5%). For this reason, we determined that our desired mouse model should be generated
using a genome-editing technique, as opposed to traditional breeding methods (Figure
1.8B). Considering the various genome-editing techniques that are presently available,
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we decided to use the CRISPR/Cas9 method to generate our mouse model because of the
convenience in experimental design and the knockout efficiency. This genome-editing
technique ensures that the Fxr-null allele and the floxed Tdg allele are present within the
same chromatid, resulting in co-segregation of Tdg and Fxr alleles during genetic
recombination. Moreover, this strategy provides us the added benefit of generating a
novel Fxr-null mouse model in a floxed Tdg background.
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Figure 1.8 Experimental approach behind generation of Fxr-null mice. A) Tdg and
Fxr are located on mouse chromosome 10 separated by ~10 Mb. B) Tdgflox/flox sperm were
used to fertilize oocytes from wildtype C57BL6 mice. Single-celled embryos were
injected with Cas9 and the corresponding gRNA which targets exon 5 of Fxr. These
embryos were implanted into pseudopregnant CD-1 mice to generate founder mice with
the following genotype: Fxr–/–Tdgflox/+.
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2

Methods

2.1

Generation of TDGCKO, Fxr-null, and Tdg/Fxr DKO mice
All mouse experiments were done in compliance with the Institutional Animal

Care and Use Committee guidelines at the London Regional Cancer Center and at
Western University (Mouse Protocol Number: 2018-051). For TDGCKO mice (B6Tdgtm1(cre/ERT2)Torchia), Tdg flox/flox mice (B6-Tdgtm1Geno) were bred with UBC-cre/ERT2+/–
mice (B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J (Jackson Laboratory, Bar Harbor, ME, USA) to
generate Tdg flox/flox CreERT2+/– mice. These mice were then bred with Tdg flox/– mice to
generate the Tdg flox/– CreERT2+/– experimental genotype (TDGCKO). In this model, exon
2 of Tdg is targeted for deletion, which has previously been shown to generate an
efficient knockdown of the TDG protein. For TAM injections, TAM (Sigma, St. Louis,
MO, USA, T5648-1G) was dissolved in corn oil (Sigma, St. Louis, MO, USA, C8267)
overnight at a concentration of 20 mg/mL and stored at 4°C. Adult (8 weeks old) Tdg flox/–
CreERT2+/– and age/sex matched Tdg flox/flox controls were injected intraperitoneally with
3 mg TAM daily for 5 days to facilitate efficient TDG deletion. TAM-treated mice were
then monitored during the course of aging. All mice lines were maintained in a pure
C57BL6 background.
Fxr-null mice (B6-Nr1h4em1TorchiaTdgem1Torchia) were generated using the
CRISPR/Cas9 genome editing method. Briefly, in-vitro fertilization (IVF) was performed
by 12-hour incubation of oocytes harvested from superovulated wild-type C57BL6
females and sperm harvested from Tdg flox/flox mice. Following IVF, all fertilized one-cell
zygotes were microinjected with 5 ng of Cas9 mRNA (TriLink Biotechnologies, San
Diego, CA, USA) and 2.5 ng of the corresponding gRNA into the male pronucleus. All
injected zygotes were incubated overnight at 37°C, and all embryos that developed to the
2-cell stage were implanted into 0.5 dpc pseudopregant CD-1 females the following
morning. Founders were bred with wildtype C57BL6 mice to generate heterozygous mice
(Fxr+/– Tdg flox/+). Heterozygous mice were intercrossed to generate Fxr-null mice (Fxr–/–
Tdgflox/flox). Livers were harvested from 3-week-old Fxr-null mice and wildtype mice for
gene expression analysis and protein expression analysis.
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For Tdg/Fxr DKO mice (B6.Cg-Tg(UBCcre/ERT2)1EjbNr1h4em1TorchiaTdgem1Torchia),
Fxr-null mice were bred with UBC-cre/ERT2+/– mice, and the resulting offspring was
backcrossed to generate our working model (Fxr–/–Tdgfl/fl UBC-cre/ERT2+/–). 4-week old
Fxr–/–Tdgfl/fl UBC-cre/ERT2+/– mice and age/sex matched Fxr–/– Tdg flox/flox controls were
injected intraperitoneally with 1.3 mg TAM daily for 5 days to facilitate efficient TDG
deletion. Mice were sacrificed two weeks after the last injection, and then livers and
colons were harvested for protein expression analysis.
2.2

RT-PCR/RT-qPCR
Total RNA from liver tissues was extracted using an RNAzol solution (Sigma, St.

Louis, MO, USA) as per the manufacturer’s protocol. The cDNA was synthesized using
the Applied Biosystems Reverse Transcription Kit as per manufacturer’s protocol. For
RT-PCR, cDNA was PCR amplified using primers from Table 2.1. Samples were loaded
onto a 2% agarose gel and electrophoresed for 30 minutes at 180 V. After
electrophoresis, DNA fragments with visualized using ethidium bromide staining and
imaged using the ChemiDoc XRS imaging system (Bio-Rad, Hercules, CA, USA).
Quantitative PCR (qPCR) was performed using a SYBR Green-detection system
(Applied Biosystems, Foster City, CA, USA) using primers outlined in Table 2.2.
Transcript abundance was normalized to Gapdh mRNA.
2.3

Protein extraction and western blot
For protein extraction, tissues were homogenized in 1 ml of ice-cold RIPA lysis

buffer (150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, 50 mM TrisHCl, pH 8) containing 1x Halt Protease Inhibitor Cocktail (Thermo Scientific, Rockford,
IL, USA). Lysates were incubated on ice for 15 minutes, centrifuged at maximum speed
(13,000 x g) at 4°C for 15 minutes and the supernatant was retained. Protein
concentrations were determined using the Bradford assay. For western blot, 50 μg protein
samples were loaded onto a 4-12% gradient Bis-Tris NuPAGE gel (Invitrogen, Carlsbad,
CA, USA), subjected to SDS-PAGE, and transferred onto a PVDF membrane. PVDF
membranes were incubated in blocking buffer consisting of 5% skim milk in PBS for one
hour and hybridized overnight with the appropriate primary antibody at the indicated

38

dilution. After five ten-minute washes in blocking buffer, membranes were hybridized for
one hour with the appropriate secondary antibodies. The membranes were then washed 5
times in blocking buffer and the blots were developed using the Clarity Western ECL
Substrate (Bio-Rad, Hercules, CA, USA) and imaged using the ChemiDoc XRS imaging
system (Bio-Rad, Hercules, CA, USA). The following primary antibodies were used:
rabbit monoclonal anti-TDG (Active Motif, Carlsbad, CA, USA, 1:1000 dilution), rabbit
polyclonal anti-FXR (Abcam, Cambridge, MA, USA, ab85606, 1:1000 dilution), mouse
monoclonal anti-Vinculin (Abcam, Cambridge, MA, USA, ab130007, 1:20,000 dilution).
2.4

Immunoprecipitation
Liver tissue (~30 mg) was homogenized in 1 ml of lysis buffer (20 mM Tris-HCl

pH 8.0, 0.5 mM EDTA, 0.5% NP40, 100 mM NaCl, 1 mM MgCl2). Then 150 U of the
Benzonase nuclease (Sigma, St. Louis, MO, USA) was added to the lysate, and the
mixture was rocked at 4°C for 40 minutes. The lysate was then cleared by centrifugation
at maximum speed (13,000 x g) for 30 minutes at 4°C, and the supernatant was collected.
5 mg of FXR or IgG antibody was pre-mixed with 50 ml of protein A/G Dynabeads, and
subsequently crosslinked using Bissulfosuccinimidyl suberate (BS3) (Thermo Scientific,
Rockford, IL, USA) for 40 minutes at room temperature. The BS3 was quenched using 20
mM Tris-HCl, pH 8.0 and then 1 mg of protein from the cleared lysate was diluted tenfold in buffer A (20 mM Tris-HCl pH 8.0, 0.5 mM EDTA, 0.05% NP40, 150 mM NaCl,
1 mM MgCl2) and incubated with 50 μl of the crosslinked Dynabeads overnight. The
Dynabeads were then washed 10 times using buffer A, eluted using the LDS running
buffer and analyzed by western blot. 5% of the cleared lysate (input) was used to
normalize loading.
2.5

RNASeq analysis
RNA sample quality was assessed using the Agilent 2100 Bioanalyzer. RNA

samples were then prepped following the standard protocol for the NEBnext Ultra ii
Stranded mRNA (New England Biolabs, Beverly, MA, USA) at the University of British
Columbia. Sequencing was performed on the Illumina NextSeq 500 with Paired End 42
bp × 42 bp reads. The raw data was aligned to the mm10 mouse genome using the STAR
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aligner and the gene list was generated using cufflinks (Trapnell et al., 2010). A list of
differentially expressed genes was generated using q < 0.05 as the cutoff for significance.
This RNASeq data was compared with published FXRKO RNASeq data from Anakk et al.
(2011) to generate an overlap of the downregulated and upregulated genes between
TDGCKO and FXRKO mice.
2.6

CRISPR/Cas9 genome editing
gRNAs were designed and synthesized using the EnGen sgRNA synthesis kit

(New England Biolabs, Beverly, MA, USA), as per the manufacturer’s protocol (Table
2.4). gRNAs were purified using the Monarch RNA Cleanup Kit (New England Biolabs,
Beverly, MA, USA), as per the manufacturer’s protocol. For the gRNA targeting assay,
gRNAs (2.5 ng) were microinjected into wildtype, single-cell embryos along with Cas9
mRNA (5 ng). DNA was then extracted at the blastocyst stage using the Monarch
Genomic DNA Purification kit (New England Biolabs, Beverly, MA, USA), as per the
manufacturer’s protocol. DNA was PCR amplified and then incubated with Bsu36I or
HindIII (New England Biolabs, Beverly, MA, USA) restriction enzymes for 90 minutes
at 37°C (Table 2.3). Samples were loaded onto a 2% agarose gel and electrophoresed for
1 hour at 100 V. For genotyping, tail snips were collected from mouse pups and digested
using the DirectPCR Lysis reagent (Viagen, Los Angeles, CA, USA) for DNA analysis,
as per the manufacturer’s protocol. For sequencing of the mutant Fxr allele, DNA from
founder mice was PCR amplified and cloned using TA cloning kit (Invitrogen, Carlsbad,
CA, USA) as per the manufacturer’s protocol. Clones were subjected to Bsu36I digest
prior to sequencing at the Robarts Sequencing Facility.
2.7

Total bile acid analysis
Liver tissue (~30 mg) was homogenized in 1 ml of 70% ethanol and then

incubated at 50°C for 2 hours. The homogenate was centrifuged at 8,000 x g and the
supernatant was vacuum-dried, resuspended in 200 mL of water, aliquoted and kept at
80°C until analysis. For BA analysis, the Total Bile Acid Assay Enzyme Cycling Method
Kit (Diazyme, San Diego, CA, USA) was used with modifications. Briefly, prior to
analysis the calibration curve was made using serial dilutions of 50 mM cholic acid (5
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mM – 50 mM). The BioTek Synergy H4 Hybrid reader was used to analyze the samples
at 37°C over a 4-minute period, with readings taken every 30 s at 405 nm. The calibration
curve was generated by taking the difference between OD405 readings from 30 s and 4
minutes and correlating to concentration of standard used. Then, 4 mL of the liver
ethanolic extract was used for analysis and the concentration of BAs was determined
using the standard calibration curve.
2.8

Primer sequences
Table 2.1 Primers for RT-PCR

Gene

Forward (5’ – 3’)

Reverse (5’ – 3’)

FXR exon 1

GTGTGAAGCCAGCTAAAGGTATGC

TGTGGCTGAACTTGAGGAAACGG

FXR exon 5

GCTGATCAGACAGCTAATGAGG

GTGATTTCCTGAGGCATTC

FXR exon 9

CCTCTCTCCAGACAGAC

GGTTCTCAGGCTGGTACATCTTGC

Table 2.2 Primers for RT-qPCR
Gene
NR4A1
IGFBP2
IRS1
FXR
SHP
CYP7A1
CYP8B1
HSD3B7
HSDB3B
ABCC2
ABCC3
ABCC4
NTCP
BSEP
PEPCK
G6PASE
GAPDH

Forward (5’ – 3’)
Reverse (5’ – 3’)
GTGGGCATGGTGAAGGAAGTTG
AGGGAAGTGAGAAGATTGGTAGGG
GCCGGTACAACCTTAAGCAGTG
TGCTGCTCGTTGTAGAAGAGATGG
ACTATGCCAGCATCAGCTTCCAG
TCTGCTGTGATGTCCAGTTACGC
GCTGATCAGACAGCTAATGAGG
GTGATTTCCTGAGGCATTC
GCCTGAGACCTTGGTGCCCTG
CTGCCCACTGCCTGGATGC
TCAATACCATGCTTTTGTCTGC
GACCTGCACAGCATCCACT
GCCCTTACTCCAAATCCTACCA
TCGCACACATGGCTCGAT
TGGTGGATGTGTTTGGGAAGGC
ATTCTGTGTGCCCTGCACGTTG
ACCAGCTGCGATCCAGAAACCTTC
TACGTGACACTGGAGATGGTCAGC
TCTGTCCAACGCCCTCAACATC
TCTGACGTCATCCTCACTAGCC
TGAGATCGTCATTGATGGGC
AGCTGAGAGCGCAGGTCG
TTAGATGGGCCTCTGGTTCT
GCCCACAATTCCAACCTTT
CACCATGGAGTTCAGCAAGA
AGCACTGAGGGGCATGATAC
GGTTGGTGGACATTAACAGCG
CCTAGGATAAGGACAGCCACACC
GGCCACAGCTGCTGCAG
GGTCGCATGGCAAAGGG
CAGTGGTCGGAGACTGGTTC
TATAGGCACGGAGCTGTTGC
CCAGAACATCATCCCTGC
CTTGGCAGGTTTCTCCAGGC
Table 2.3 Primers for genotyping
FXR forward
FXR reverse

ATATGCCTTTGACCGCCCTC
GGCACACTTTACATATTTCAAGAAC
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FXR reverse (47bp deletion)

CACATTTACATATAAATCCCACC

Table 2.4 gRNA oligos
FXR
gRNA 1 TTCTAATACGACTCACTATAGCAACAAACAGAGAATGCCTCGTTTTAGAGCTAGA
FXR
gRNA 2 TTCTAATACGACTCACTATAGAATTCACAAAAAAGCTTCCGTTTTAGAGCTAGA

42

3

Results

3.1

Determining the molecular role of TDG in FXR signaling
Our lab generated conditional Tdg knockout (TDGCKO) mice using the Cre-ERT2

mouse model as described in Section 1.3.2. In this model, adult (8-week old) Tdg flox/–
CreERT2+/– mice were intraperitoneally injected with 15 mg TAM over a 5-day period
and monitored during the course of aging. We observed that these mice develop a late
onset HCC as early as 17-months post-TAM, and this phenotype was more prevalent in
males compared to females (Hassan et al., 2020). Moreover, this hepatocarcinogenic
phenotype was associated with increased body weight, glucose intolerance, and BA
overload (Hassan et al., 2020).
To investigate the transcriptional profile of TDGCKO mice, RNAseq analysis was
performed using the pre-tumour livers and hepatocarcinogenic livers of male TDGCKO
mice and age/sex matched controls. Transcriptomic analysis revealed that metabolism
and the primary BA synthetic pathway were highly dysregulated following Tdg deletion
(Hassan et al., 2020). This finding, along with the phenotypic similarities between
TDGCKO mice and FXRKO mice, prompted us to compare the transcriptional profiles of
FXRKO and TDGCKO mice. Interestingly, comparison of these transcriptional profiles
showed a significant overlap (~25%) of dysregulated genes, suggesting that TDG and
FXR are involved in common molecular pathways (Figure 3.1). To validate the
transcriptomic analysis of TDGCKO mice, the expression of several upregulated and
downregulated genes were analyzed using qPCR, including genes involved in insulin
signaling, FXR signaling, BA synthesis, and BA transport (Figure 3.2). We found that
this qPCR analysis was consistent with the RNAseq analysis of TDGCKO mice.
Based on the comparison of the transcriptional profiles of FXRKO and TDGCKO
mice, we speculated that TDG participates in the FXR signaling pathway. Furthermore, it
is well-established that TDG interacts with various nuclear receptors as a transcriptional
coactivator although direct associations between TDG and FXR have not been previously
investigated. To explore the potential interaction between TDG and FXR, coimmunoprecipitation experiments were performed using wildtype mouse livers. We
43

demonstrated a novel interaction between TDG and FXR in vivo (Figure 3.3). Altogether,
these results suggest that TDG may function as a co-activator of FXR signaling.
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Figure 3.1 Transcriptional overlap between TDGCKO and FXRKO mice. Overlap of
the downregulated and upregulated genes between age/sex matched TDGCKO and FXRKO
livers. Pathway analysis of the upregulated and downregulated genes was performed
using the KEGG and REACTOME databases. RNAseq data from male FXRKO livers
were obtained from Anakk et al. (2011).
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Figure 3.2 qPCR analysis of TDGCKO mice. mRNA was isolated from the livers of
control mice (Tdg fl/fl) and 4-month old (post-tamoxifen) TDGCKO mice. qPCR analysis
(n=3) was performed on genes involved in: A) insulin signaling B) FXR signaling C)
primary BA synthesis and D) BA transport. T-test p-values: *p<0.05, **p<0.01.
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Figure 3.3 Co-immunoprecipitation of TDG and FXR. Immunoprecipitation was
performed in the livers of wildtype mice using an FXR antibody. Lysates were pretreated
with benzonase nuclease prior to immunoprecipitation. The immunoprecipitated material
was then analyzed by western blot using FXR and TDG antibodies. 5% of the cleared
lysate (input) was used to normalize loading.
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3.2

CRISPR/CAS9-mediated generation of mutant Fxr allele
My goal is to generate Tdg/Fxr DKO mice, with the hope of producing a more

accelerated HCC mouse model. Based on the proximity of the Tdg and Fxr genes as
described in Section 1.4, we used the CRISPR/Cas9 method to generate this mouse
model. For the gRNA design, we targeted an exon of FXR which is common to all
isoforms to ensure that the gRNA-mediated deletion event resulted in an Fxr-null allele.
To validate our experimental approach, we designed two guide RNAs (gRNAs): gRNA 1
targets exon 5 of the full-length FXR; whereas gRNA 2 targets exon 6 of the full-length
FXR. These gRNAs were synthesized in vitro and purified, yielding concentrations of 27
ng/µl (gRNA 1) and 6 ng/µl (gRNA 2) (Figure 3.4A). Exons 5 and 6 contain a Bsu36I
restriction site and a HindIII restriction site, respectively. If the gRNA is successfully
targeted to its respective site, Cas9 will induce a double stranded break in the DNA ~3 bp
upstream of the PAM site (NGG), which is present within each restriction site. This
double stranded break is then repaired through the error-prone process of nonhomologous
end joining (NHEJ), resulting in the formation of indels and subsequent alteration of the
restriction site (Sander and Joung, 2014). Hence, a successful gRNA-targeting event is
identified as a non-cleavage event following restriction enzyme treatment (Figure 3.4B).
gRNAs 1 and 2 were injected into 14 embryos and 29 embryos respectively, and the
success rates observed for Fxr-targeting using gRNA 1 and gRNA 2 were 62% and 20%,
respectively. Based on the higher targeting efficiency of gRNA 1, we used this gRNA to
generate our Fxr-null mice.
After validating the experimental approach through successful gRNA targeting, in
vitro fertilization (IVF) was performed using oocytes from wildtype C57BL6 mice and
Tdgflox/flox sperm. Single-cell embryos were injected with gRNA 1 and implanted into
pseudopregnant CD-1 mice to generate 5 Fxr–/–Tdgflox/+ founder mice (Figure 3.5). We
bred these founders with wildtype C57BL6 mice to generate Fxr+/– Tdgflox/+ offspring,
confirming co-segregation of Tdg and Fxr alleles. To identify the mutation caused by
gRNA-mediated deletion of Fxr in each of the 5 founders, we PCR-amplified and
subcloned the 631-bp fragment corresponding to exon 5 of the full-length FXR, which
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encodes a small segment of the hinge domain and the ligand-binding domain. We
generated six clones for each of the five mutant alleles, amounting to 30 clones in total.
Prior to sequencing, DNA from each clone was subjected to Bsu36I treatment to confirm
that the restriction site was altered due to an indel mutation. Sequencing analysis of
clones resistant to Bsu36I digest revealed that the gRNA-mediated mutation that occurred
was a 47-bp deletion (Figure 3.6A). This specific deletion event occurred in four of the
five mutant alleles. Based on this sequencing analysis, I predicted that this deletion event
should produce a premature stop codon within exon 5. To validate these sequencing
results, I designed primers to target this 47-bp deletion. Using agarose gel
electrophoresis, I confirmed that the mutant Fxr allele is 47 bp shorter in length than the
wildtype Fxr allele (Figure 3.6B). Advantageously, the use of these primers allowed us to
bypass the need for Bsu36I treatment to confirm the presence of a mutation. Furthermore,
in this 47-bp deletion event that occurred, 25 bp of exonic sequence were deleted within
exon 5. To validate this, I performed RT-PCR using primers specific to this 25-bp
deletion of exonic sequence (Figure 3.6C). Using agarose gel electrophoresis, I confirmed
that these primers did not amplify the 25-bp sequence within exon 5 in Fxr–/– mice.
Collectively, these results demonstrate that gRNA-mediated targeting of Fxr generated a
47-bp deletion in exon 5.
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Figure 3.4 gRNA-mediated targeting of Fxr. A) gRNAs 1 and 2 were synthesized in
vitro and purified using the Monarch RNA Cleanup Kit, yielding concentrations of 27
ng/µl (gRNA 1) and 6 ng/µl (gRNA 2). A control gRNA was also synthesized in vitro.
Samples were loaded onto a 10% TBE-Urea gel and electrophoresed for 1 hour at 180 V.
B) Single-cell embryos were injected with Cas9 mRNA and one of two different guide
RNAs. DNA was extracted from these embryos, PCR amplified, and then cleaved with
Bsu36I or HindIII. Samples were loaded onto a 2% agarose gel and electrophoresed for 1
hour at 100 V. The 631-bp band corresponds to the undigested Fxr amplicon. The 503-bp
and 128-bp bands represent Bsu36I-digested DNA fragments. The 539-bp and 62-bp
bands represent HindIII-digested DNA fragments.
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Figure 3.5 Generation of five founder mice. Single-cell embryos were injected with
5ng of Cas9 mRNA and 2.5ng of gRNA 1 which targets exon 5 of Fxr. Embryos were
implanted into pseudopregnant CD-1 mice to generate 5 founder mice (M1-M5). DNA
was extracted from newborn pups, PCR amplified, and then cleaved with Bsu36I.
Samples were loaded onto a 2% agarose gel and electrophoresed for 1 hour at 100 V. The
631-bp band corresponds to the undigested Fxr amplicon. The 503-bp and 128-bp bands
(in wildtype) represent Bsu36I-digested DNA fragments. DNA from a founder mouse
(Pup) that did not survive was also PCR amplified and cleaved with Bsu36I.
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Figure 3.6 A 47-bp deletion event at exon 5 of FXR. A) Founder mice (Fxr–/– Tdg fl/+)
were bred with wildtype C57BL6 mice to produce Fxr+/–Tdgfl/+ offspring. DNA was
extracted from these mice and a 631-bp fragment of Fxr was PCR amplified and cloned.
Clones resistant to Bsu36I digestion were sequenced at the Robarts Sequencing Facility.
B) DNA was extracted from wildtype mice (WT; Fxr+/+ Tdg +/+), heterozygous mice
(Het; Fxr+/– Tdg fl/+), and Fxr-null mice (KO; Fxr–/– Tdg fl/ fl), and then PCR amplified.
Samples were loaded onto a 2% agarose gel and electrophoresed for 30 minutes at 180 V.
C) RNA from wildtype mice, heterozygous mice, and knockout mice was reverse
transcribed. The resulting cDNA was PCR amplified, and samples were loaded onto a 2%
agarose gel and electrophoresed for 30 minutes at 180 V.
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3.3

Generation of Fxr-null mice
The 25 bp of exonic sequence that was deleted following NHEJ encodes the start

of the ligand-binding domain of FXR. This deletion event is predicted to generate a
premature stop codon at the start of the ligand-binding domain. Therefore, any FXR
protein produced in Fxr–/– mice is expected to be truncated and/or degraded. To confirm
this, we generated Fxr-null (Fxr–/– Tdgflox/flox) mice by breeding Fxr-het (Fxr+/– Tdgflox/+)
mice together. Using an FXR antibody that specifically recognizes the amino-terminal
region of FXR, I found that FXR was not detected in the livers of 3-week old Fxr-null
mice by western blotting (Figure 3.7A). Interestingly, a faint band was detected at 30 kDa
in Fxr-null mice, which corresponds with the predicted molecular weight of the putative
truncated FXR protein (Figure 3.7A). The presence of this band suggests that a truncated
FXR protein is formed in Fxr-null mice. As expected, TDG expression was detected in
the livers of 3-week old Fxr-null mice (Figure 3.7B) and no notable difference in
expression was detected compared to wildtype. To measure the transcriptional changes
caused by FXR deficiency, I performed qPCR analysis on several FXR target genes
involved in FXR signaling, glucose metabolism, BA synthesis, or BA transport. I found
that Shp was downregulated 4-fold in the livers of 3-week old Fxr-null mice compared to
age-matched controls (Figure 3.8A). Accordingly, Cyp7a1 and Cyp8b1, both involved in
BA synthesis, were upregulated 2-fold and 4-fold in Fxr-null mice, respectively,
indicating severe dysregulation of BA synthesis (Figure 3.8B). Moreover, Bsep, a key BA
transporter, was downregulated 1.5-fold in Fxr-null (Figure 3.8C). In terms of glucose
metabolism, Pepck and G6Pase were downregulated 4-fold and 3-fold in Fxr-null mice,
respectively (Figure 3.8D), indicating dysregulation of glucose metabolism. Based on the
dysregulation of genes involved BA synthesis in Fxr-null mice, I measured the total BA
levels in the livers of 3-week old Fxr-null mice. I found that the total hepatic BA levels
were significantly higher in Fxr-null mice compared to age-matched controls (Figure
3.9). Collectively, these results demonstrate that Fxr-null mice display significant
dysregulation of BA and glucose metabolism. These results are consistent with findings
from Fxr-null mice generated by conventional methods.
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Figure 3.7 Western blot analysis of Fxr-null mice. Protein extracts were collected from
livers of 3-week old wildtype mice (WT; Fxr+/+ Tdg +/+), heterozygous mice (Het; Fxr+/–
Tdg fl/+), and Fxr-null mice (KO; Fxr–/– Tdg fl/ fl). A) 50 µg extracts were analyzed by
western blot using Fxr and Vinculin antibodies. B) 50 µg extracts were analyzed by
western blot using Tdg and Vinculin antibodies.
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Figure 3.8 qPCR analysis of Fxr-null mice. mRNA was isolated from the livers of 3week old wildtype (WT) mice and Fxr-null mice (KO). mRNA levels for the following
genes were analyzed by qPCR (n=3): A) Fxr and Shp (FXR signaling) B) Cyp7a1 and
Cyp8b1 (BA synthesis) C) Ntcp, Abcc2, and Bsep (BA efflux) D) G6Pase and Pepck
(Glucose metabolism). T-test p-values: *p<0.05, **p<0.01, ***p<0.001.
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Figure 3.9 Hepatic bile acid levels of Fxr-null mice. Total bile acids were isolated from
the livers of 3-week old wildtype (WT) mice and Fxr-null mice (KO). Bile acid levels
were analyzed using the Total Bile Acid Assay Enzyme Cycling Method Kit (Diazyme)
(n=2). T-test p-values: *p<0.05.
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3.4

Generation of Tdg/Fxr DKO mice
We have demonstrated the successful generation of Fxr-null mice using

CRISPR/Cas9. We have confirmed the co-segregation of Tdg and Fxr alleles in these
mice, which will facilitate the generation of Tdg/Fxr DKO mice. The breeding strategy
for generating Tdg/Fxr DKO mice is outlined in Figure 3.10. We bred Fxr-null mice with
Fxr+/– Tdg flox/+ CreERT2+/– mice to generate our working model (Fxr–/– Tdg flox/flox
CreERT2+/–). 4-week old Fxr–/– Tdg flox/flox CreERT2+/– mice and age/sex matched Fxr–/–
Tdg flox/flox controls were intraperitoneally injected with 6.5 mg of TAM over a 5-day
period (Figure 3.11A). After TAM injections, I did not observe any considerable
differences in the overall health of the mice. 2 weeks post-TAM, the liver and colon of
DKO mice were harvested for protein expression analysis. In the DKO mice, neither
TDG nor FXR expression were detected based on western blotting. (Figure 3.11B, C).
Altogether, these results demonstrate that Cre-ERT2 induction by TAM resulted in a
conditional knockout of TDG in Fxr–/– Tdg flox/flox CreERT2+/– mice.
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Figure 3.10 Breeding scheme for Tdg/Fxr double knockout (Fxr–/–Tdgfl/fl UBCcre/ERT2+/–) mice. Fxr–/–Tdgfl/+ founders were bred with wildtype C57BL6 mice to
ensure that the Fxr-null allele is carried through the germline. Then, Fxr+/–Tdgfl/+ mice
were intercrossed to generate Fxr-null mice (Fxr–/–Tdgfl/fl). Fxr-null mice were bred with
UBC-cre/ERT2+/– mice, and the resulting offspring was backcrossed to generate our
working model (Fxr–/–Tdgfl/fl UBC-cre/ERT2+/–).
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Figure 3.11 Generation of Tdg/Fxr double knockout mice. A) 4-week old Fxr–/– Tdg
flox/flox

CreERT2+/– mice were injected with 6.5 mg of tamoxifen over a 5-day period.

Tissues were harvested 2 weeks post-TAM for expression analysis. B) 50 µg protein
extracts from wildtype mice (WT; Fxr+/+ Tdg +/+), control mice (C; Fxr–/– Tdg flox/flox), and
double-knockout mice (DKO; Fxr–/– Tdg –/– UBC-cre/ERT2+/–) were analyzed by western
blot using Fxr and Vinculin antibodies. C) 50 µg protein extracts from wildtype mice
(WT; Fxr+/+ Tdg +/+), control mice (C; Fxr–/– Tdg flox/flox), and double-knockout mice
(DKO; Fxr–/– Tdg –/– UBC-cre/ERT2+/–) were analyzed by western blot using Tdg and
Vinculin antibodies.
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4

Discussion

4.1

Overview
In this study, we established a novel association between TDG and FXR. We also

generated a novel Fxr-null mouse model using CRISPR/Cas9 genome editing. In this
model, the Fxr-null allele is linked to a floxed Tdg allele, allowing for co-segregation of
these alleles during genetic recombination. Additionally, this mouse model facilitated the
subsequent generation of Tdg/Fxr DKO mice through the function of the tamoxifeninducible Cre-ERT2. Through sequencing analysis, we showed that the CRISPR/Cas9mediated mutation that occurred at the Fxr-null allele was a 47-bp deletion within exon 5
and its adjacent intron. This deletion event resulted in the formation of a premature stop
codon in the ligand-binding domain of FXR, resulting in no FXR expression in the livers
of Fxr-null mice based on western blotting. Moreover, we showed that Fxr-null mice
display impaired BA and glucose metabolism as early as 3 weeks post-partum.
4.2

TDG’s role as a coactivator of FXR signaling
TDG is known to function as a transcriptional coactivator through its interaction

with nuclear receptors. In this study, we aimed to investigate the relationship between
TDG and FXR at the molecular level. Initially, when we compared the phenotypes of
TDGCKO mice and Fxr-null mice, we found that there were many similarities, including
late-onset HCC, glucose intolerance, and BA overload. Moreover, when we compared the
transcriptional profiles of both mouse models, we found that there was a 25% overlap of
dysregulated genes. Several genes contained in this overlap were involved in BA
metabolism and glucose metabolism, indicating that TDG and FXR share a common
function in these pathways. These findings suggested that TDG may be involved in FXR
signaling as a transcriptional coactivator. In support of this notion, we showed that TDG
and FXR co-immunoprecipitated using wildtype mouse livers, demonstrating a novel
interaction between TDG and FXR in vivo. Taken together, these findings support my
hypothesis that TDG is an essential coactivator of FXR signaling in the liver.
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4.3

Alteration of the Fxr allele using CRISPR/Cas9
Another key aim of this study was to generate Tdg/Fxr DKO mice. The genetic

linkage of Tdg and Fxr prevented us from generating DKO mice through traditional
breeding methods. Therefore, we utilized CRISPR/Cas9 genome editing to generate our
novel Fxr-null mouse model. Prior to the generation of this mouse model, we validated
our CRISPR/Cas9 strategy by experimenting with two different gRNAs. Each gRNA
targets a different region of Fxr, and we found that gRNA 1 had a higher targeting
efficiency compared to gRNA 2. This observation can be attributed to the limitations in
our targeting validation assay. The validation assay was designed such that a successful
targeting event would be identified as a non-cleavage event following restriction enzyme
treatment, as the presence of Cas9 and the gRNA should alter the restriction site through
NHEJ. However, based on the difference in position of the PAM sequence in the Bsu36I
restriction site compared to the HindIII restriction site, a larger portion of the restriction
site would be altered using gRNA 1 compared to gRNA 2. Consequently, successful
targeting events are less likely to be observed using gRNA 2 compared to gRNA 1. This
limitation may have contributed to the higher targeting efficiency observed using gRNA
1.
Recognition of the target sequence by the gRNA should induce a double-stranded
break by Cas9 ~3 bp upstream of the PAM sequence. Interestingly, through sequencing
analysis, I observed that the Cas9 excision occurred 5 bp upstream of the PAM sequence
in exon 5 of FXR. Moreover, I observed that this specific excision event resulted in the
same DNA repair event (47-bp deletion) in four of the five mutant Fxr alleles. In fact, the
unique Fxr mutant allele contained this 47-bp deletion in addition to a 43-bp insertion
immediately upstream. Numerous studies have demonstrated that the CRISPR/Cas9
system displays high editing efficiency (Hwang et al., 2013; Bassett et al., 2013; Hu et
al., 2018). Likewise, we demonstrated that the founder mice did not display mosaicism,
as the mutant Fxr allele was carried through the germline during breeding. Altogether, we
showed that the CRISPR/Cas9 system was highly efficient in editing the wildtype Fxr
allele.
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4.4

Comparison of previous Fxr-null mouse models
In our Fxr-null mouse model, 25 bp of exonic sequence were deleted within exon

5 along with 22 bp of intronic sequence. This deletion event caused a frameshift mutation
that generated a premature stop codon in exon 5 of FXR. Through RT-PCR, I showed
that the nascent Fxr transcript was produced in Fxr-null mice; however, the deleted
region within exon 5 was not detected. In comparison with previous FXRKO mouse
models, only Kok et al. (2003) showed that no Fxr transcript was produced in their
FXRKO model. The premature stop codon generated in our Fxr-null mouse model is at
position 272 of FXR, which encodes the start of the ligand-binding domain. The presence
of this stop codon should result a truncated FXR protein that is nonfunctional, as it does
not possess a ligand-binding domain. This truncated FXR protein was detected in Fxrnull mice, however its levels were noticeably lower compared to the FXR protein that
was present in wildtype mice. These observations suggest that although a truncated FXR
protein is expressed in Fxr-null mice, it is partially degraded.
Previous FXRKO mouse models display BA overload between 8-12 weeks of age
(Sinal et al., 2000; Kok et al., 2003). In this study, we demonstrated that Fxr-null mice
display BA overload as early as 3 weeks of age. qPCR analysis of Fxr-null mice showed
that the BA synthesis genes Cyp7a1and Cyp8b1 were significantly upregulated in Fxrnull mice, supporting the hepatic BA overload displayed in our mice. This finding is in
accordance with Sinal et al. (2000) and Kok et al. (2003), as both studies showed
upregulation of Cyp7a1and Cyp8b1. Furthermore, I showed that Shp, a key regulator of
BA homeostasis, was significantly downregulated in Fxr-null mice. Also, the hepatic BA
transporter Bsep was significantly downregulated in Fxr-null mice. These findings are in
accordance with Sinal et al. (2000) and Kok et al. (2003), as both studies showed
significant downregulation of Shp and Bsep. The gluconeogenic genes Pepck and G6Pase
were significantly downregulated in Fxr-null mice, indicating that FXR deficiency
caused a downregulation of hepatic gluconeogenesis. Likewise, Zhang et al. (2006)
demonstrated Pepck and G6Pase downregulation in FXRKO mice. Altogether, the
findings in our Fxr-null model are largely consistent with previous FXRKO mouse
models.
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4.5

Cre-mediated knockout of TDG in Tdg/Fxr DKO mice
The conditional knockout of TDG in adult mice (8-week old) has been previously

demonstrated in our lab using the TAM-inducible Cre-ERT2. In this study, we
demonstrated the conditional knockout of TDG in 4-week old Fxr–/– Tdg flox/flox
CreERT2+/– mice. Because this model contains two floxed Tdg alleles as opposed to the
one floxed allele in our TDGCKO model, I performed the TAM injection at an earlier
timepoint. This increases the probability of observing the hepatocarcinogenic phenotype
observed in TDGCKO mice. Although TDG is likely to be a coactivator of FXR signaling,
we speculated that Tdg is not epistasic to Fxr because TDG functions in many pathways
aside from FXR signaling. Furthermore, Anakk et al. (2011) demonstrated that Fxr is not
epistatic to Shp, even though both genes function linearly in the BA synthetic pathway.
Therefore, I expect that the phenotype displayed in Tdg/Fxr DKO mice will be more
severe than that of either knockout alone.
4.6

Summary and future directions
Overall, the aims of this study were to characterize the molecular role of TDG in

FXR signaling, and to generate and characterize Tdg/Fxr DKO mice. Through
transcriptomic analysis and co-immunoprecipitation experiments, we implicated TDG as
a coactivator of FXR signaling. In addition to generating Tdg/Fxr DKO mice, we
generated a novel Fxr-null mouse model using CRISPR/Cas9. The mutant Fxr allele that
was generated through CRISPR/Cas9 contained a 47-bp deletion that resulted in the
formation of a premature stop codon within exon 5 of FXR. This deletion event resulted
in an Fxr-null allele that was not detected at the protein level. Our Fxr-null model
displayed phenotypic traits consistent with that of previous FXRKO models, including
dysregulation of glucose metabolism and BA overload.
In the future, we will be further characterizing the Fxr-null mice and the DKO
mice through aging studies to monitor for the development of HCC. Also, the epigenetic
status of DKO mice will be investigated to determine whether loss of Tdg in Fxr-null
mice causes epigenetic defects that accelerate the development of HCC. These potential

74

findings will provide insight into the epigenetic abnormalities involved in HCC
development.
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